Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Senti Biosciences Inc (SNTI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: SNTI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $13.5
1 Year Target Price $13.5
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -74.84% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 40.03M USD | Price to earnings Ratio - | 1Y Target Price 13.5 |
Price to earnings Ratio - | 1Y Target Price 13.5 | ||
Volume (30-day avg) 1 | Beta 2.07 | 52 Weeks Range 1.46 - 10.00 | Updated Date 08/15/2025 |
52 Weeks Range 1.46 - 10.00 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -8.52 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.55 | Actual -0.56 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -45.98% | Return on Equity (TTM) -169.54% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 49760115 | Price to Sales(TTM) 55.46 |
Enterprise Value 49760115 | Price to Sales(TTM) 55.46 | ||
Enterprise Value to Revenue 134.22 | Enterprise Value to EBITDA -0.28 | Shares Outstanding 26160200 | Shares Floating 11911527 |
Shares Outstanding 26160200 | Shares Floating 11911527 | ||
Percent Insiders 57.04 | Percent Institutions 29.41 |
Upturn AI SWOT
Senti Biosciences Inc
Company Overview
History and Background
Senti Biosciences, Inc. (Senti Bio) was founded in 2016. It is a biotechnology company focused on developing gene circuits to create advanced medicines.
Core Business Areas
- Gene Circuit Platform: Development of synthetic biology platforms to design and manufacture gene circuits for cell and gene therapies. These circuits are designed to precisely control cell behavior.
- Oncolytic Virus Program: Engineered oncolytic viruses designed to selectively target and destroy cancer cells.
- Cell Therapy Program: Engineered NK cell therapies designed to selectively target and destroy cancer cells.
Leadership and Structure
The company is led by a management team with experience in synthetic biology and drug development. Timothy Lu is the CEO. The structure includes research and development, clinical operations, and business development teams.
Top Products and Market Share
Key Offerings
- SENTI-202: SENTI-202 is an off-the-shelf CAR-NK cell therapy candidate that incorporates a logic gated circuit designed to target and eliminate tumors expressing specific antigens. It is currently in Phase 1 clinical trials. Competitors include NK cell therapies from companies such as Affimed and Fate Therapeutics.
- SENTI-301: SENTI-301 is an oncolytic virus expressing logic gated circuit designed to target and eliminate tumors. It is currently in preclinical development. Competitors include Oncolytic virus from companies such as Replimune.
Market Dynamics
Industry Overview
The gene and cell therapy market is rapidly growing, driven by advancements in synthetic biology and the potential to address unmet medical needs. It is characterized by high R&D costs, regulatory complexity, and competition.
Positioning
Senti Bio is positioned as a pioneer in the field of gene circuit-based cell and gene therapies, focusing on developing programmable medicines. Their competitive advantage lies in their proprietary gene circuit platform, which aims to provide greater precision and control in cell behavior.
Total Addressable Market (TAM)
The TAM for gene and cell therapies is projected to reach hundreds of billions of dollars in the coming years. Senti Bio is targeting specific oncology indications within this market. Based on analyst reports, the cell and gene therapy market is expected to reach $75 billion by 2030. Senti Bio is positioned to capture a share of this market by developing differentiated cell therapies.
Upturn SWOT Analysis
Strengths
- Proprietary gene circuit platform
- Strong intellectual property portfolio
- Experienced management team
- Early-stage clinical programs
Weaknesses
- Early stage of development
- Limited financial resources compared to larger competitors
- High R&D risk
- Dependence on partnerships for manufacturing and commercialization
Opportunities
- Expanding applications of gene circuits in cell and gene therapies
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Advancements in manufacturing technologies
Threats
- Regulatory hurdles and approval timelines
- Competition from established pharmaceutical companies
- Technological advancements by competitors
- Unfavorable clinical trial outcomes
Competitors and Market Share
Key Competitors
- BMY
- GILD
- BLUE
Competitive Landscape
Senti Bio faces competition from larger pharmaceutical companies with established cell and gene therapy programs. Its advantage lies in its unique gene circuit platform. However, it is at a disadvantage due to its smaller size and limited resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited as the company is in the early stages of clinical development.
Future Projections: Future growth depends on the success of its clinical programs and partnerships. Analyst estimates suggest potential for significant growth if clinical trials are successful.
Recent Initiatives: Recent initiatives include advancing SENTI-202 into Phase 1 clinical trials and expanding its collaboration with Bayer.
Summary
Senti Bio is a promising biotechnology company developing innovative gene circuit-based cell and gene therapies. Its strength lies in its novel platform and early-stage clinical programs. However, it faces challenges related to funding, competition, and regulatory hurdles. The company's future success depends on achieving positive clinical trial outcomes and securing strategic partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Senti Biosciences Investor Relations
- SEC Filings
- Analyst Reports
- Company Presentations
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. The analysis is based on publicly available data and may not be entirely accurate or complete. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Senti Biosciences Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2022-06-09 | Co-Founder, CEO & Director Dr. Timothy K. Lu M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 34 | Website https://www.sentibio.com |
Full time employees 34 | Website https://www.sentibio.com | ||
Senti Biosciences, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. The company's product candidates also include SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia; and SENTI-301A, an off-the-shelf CAR-NK cell therapy for the treatment of solid tumors and hepatocellular carcinoma. In addition, it develops the tumor-associated antigen and protective antigen paired discovery platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Further, its pipeline includes preclinical programs, which comprise a solid tumor cell therapy program; and partnered programs related to gene therapies for tissue-directed targets, as well as partnered programs related to cell therapies for regenerative medicines. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.